Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anfibatide and Tirofiban in Coronary Artery Disease (DPABIAP)
NCT03078257Phase 1Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2016
- Primary completion
- Nov 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anfibatide in coronary artery disease (CAD) and ST-segment elevation myocardial infarction (STEMI) (5 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: platelet aggregation at 2 hours. Status: unknown.
02
Drugs
anfibatide
03
Conditions
coronary artery disease (CAD)ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03078257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078257.